

1 Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the
2 sporozoite and protection from malnutrition
3 Mamun Kabir¹, Masud Alam¹, Uma Nayak^{2,3}, Tuhinur Arju¹, Biplob Hossain¹, Rubaiya
4 Tarannum¹, Amena Khatun¹, Jennifer A. White⁴, Jennie Z. Ma^{2,4}, Rashidul Haque¹, William A.
5 Petri Jr^{4,5,6*} and Carol A. Gilchrist⁴

6
7 ¹ International Centre for Diarrhoeal Diseases Research, Bangladesh,

8 ² Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, United
9 States of America

10 ³ Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, United
11 States of America,

12 ⁴ Department of Medicine, University of Virginia, Charlottesville, Virginia, United States of
13 America

14 ⁵ Department of Microbiology, Immunology and Cancer Biology, University of Virginia,
15 Charlottesville, Virginia, United States of America

16 ⁶ Department of Pathology, University of Virginia, Charlottesville, Virginia, United States of
17 America

18

19

20

21 **Key words:** Bangladesh; cohort study; cryptosporidiosis; children; sub-clinical, malnourished

22 ***Corresponding Author**

23 E-mail: wap3g@virginia.edu (WAP)

24

25 **Abstract**

26
27 We conducted a longitudinal study of cryptosporidiosis from birth to three years of age in an
28 urban slum of Dhaka Bangladesh. Fecal DNA was extracted from monthly surveillance samples
29 and diarrheal stool samples collected from 392 infants from birth to three years. A pan-
30 *Cryptosporidium* qPCR assay was used to identify sub-clinical and symptomatic
31 cryptosporidiosis. Anthropometric measurements were collected quarterly to assess child
32 nutritional status. 31% (121/392) of children experienced a single and 57% (222/392) multiple
33 infections with *Cryptosporidium*. Repeat infections had a lower burden of parasites in the stool
34 (Cq slope = -1.85; $p < 0.0001$) and were more likely to be sub-clinical (Chi square test for trend;
35 $p = 0.01$). Repeat infections were associated with the development of growth faltering (Pearson
36 correlation = -0.18; $p = 0.0004$). High levels of fecal IgA antibodies against the *Cryptosporidium*
37 Cp23 sporozoite protein at one year of life were associated with a delay in reinfection and
38 amelioration of growth faltering through three years of life (HAZ IgA high responders $-1.323 \pm$
39 0.932 versus HAZ -1.731 ± 0.984 $p = 0.0001$). We concluded that nonsterile immunity to
40 cryptosporidiosis in young children was associated with high levels of mucosal IgA anti-Cp23
41 and protection from diarrhea and growth faltering.

42

43 **Authors Summary**

44 *Cryptosporidium* is one of the top causes of diarrhea and growth faltering in Bangladesh infants.
45 We discovered that a prior infection resulted in incomplete immunity that protected from
46 diarrhea and growth faltering but not infection and was associated with mucosal IgA against a
47 sporozoite surface protein Cp23. The most important implication of these findings is that a
48 cryptosporidiosis vaccine may not need to achieve complete protection from infection to have a
49 beneficial impact on child health.

50

51 **Introduction**

52

53 *Cryptosporidium spp.* parasites are leading causes of diarrheal disease in infants living in low
54 and middle income countries [1–4]. They are additionally a cause of water-borne outbreaks of
55 diarrhea in high income countries and of chronic diarrhea in people living with HIV infection [5].
56 There is no vaccine and development will require an understanding of the natural history of
57 cryptosporidiosis [3,6–12]. To this end, a community-based prospective cohort study of
58 cryptosporidiosis was begun in 2014 [13]. The study subjects were born in an urban slum in
59 Dhaka, Bangladesh and enrolled during the first week of life [13–15]. In humans and in animal
60 models vaccination or prior infection resulted in partial protection against reinfection [16–19].
61 For example we observed that high fecal IgA against the sporozoite protein Cp23 delayed but
62 did not prevent a repeat infection with *Cryptosporidium spp.* [20,21]. Ajjampur et al observed a
63 decrease in the incidence of diarrhea in reinfected children [22]. In contrast Kattula et al found
64 that while the reinfection frequency was decreased the proportion of symptomatic disease was
65 unchanged [9]. In human volunteer studies second infections were associated with reduced
66 parasite burden and less severe diarrhea [23].

67

68 In addition to diarrheal disease cryptosporidiosis is associated with development of malnutrition
69 [8,24–27]. Here we report the natural history of cryptosporidiosis from a longitudinal study of
70 urban slum children from birth through three years of age in Dhaka, Bangladesh, demonstrating
71 that immunity is characterized by protection from diarrhea and growth faltering.

72

73 Results

74 Five hundred children were enrolled within the first week of birth, and of these 392 completed
 75 three years of observation. Stool samples were collected monthly and at the time of diarrhea.
 76 Successful sample collection and qPCR testing was completed for 96% of monthly surveillance
 77 time points and for 84% of the diarrheal cases (Fig 1; S1 Table 1). There were 1336
 78 *Cryptosporidium* positive samples for analysis by year 3 (Fig 1). Six hundred and ninety eight
 79 events met the definition of separate *Cryptosporidium* infections in the 392 children (Table 1).
 80 Of the 698 infections experienced by the 392 infants retained in the study at 3 years of age, 167
 81 were diarrheal and 531 sub-clinical cryptosporidiosis (Table 1). The Cq (cycle of quantification)
 82 value of the stool sample in which the parasite was first detected was used as an index of
 83 parasite burden.

84 **Fig 1. COHORT diagram.** Study subjects, collected samples and new infection numbers
 85 Abbreviations: RT-QPCR quantitative polymerase chain reaction; DS: Diarrheal samples; FU:
 86 Follow-up; MS: Monthly Samples, Cq: Cycle Quantification

87
 88 **Table 1 Frequency of Diarrheal Cryptosporidiosis in Repeated Infections**

| Cryptosporidium Infection | Number of infections | Age in days | | Infection phenotype* | | Diarrhea Frequency** | | |
|---------------------------|----------------------|---------------|------------|----------------------|--------------|----------------------|-------------|-------------|
| | | Mean \pm SD | Range | Diarrhea | Sub-clinical | Mean | Upper limit | Lower limit |
| 1st | 343 | 519 \pm 250 | [15-1088] | 96 | 247 | 0.28 | 0.33 | 0.23 |
| 2nd | 222 | 758 \pm 209 | [273-1079] | 46 | 176 | 0.21 | 0.27 | 0.16 |
| 3rd | 101 | 892 \pm 155 | [399-1084] | 17 | 84 | 0.17 | 0.26 | 0.10 |
| 4th | 28 | 939 \pm 129 | [639-1095] | 6 | 22 | 0.21 | 0.41 | 0.08 |

| | | | | | | | | |
|-----------------|---|------------------|----------------|---|---|-----|------|---|
| 5 th | 3 | 994 ± 72.5 | [929- 1072] | 0 | 3 | 0.0 | 0.70 | 0 |
| 6 th | 1 | 1067 | 1067 | 0 | 1 | 0.0 | 0.97 | 0 |

89 *Chi Square test for trend p=0.011 ** The frequency of *Cryptosporidium* associated diarrhea and
 90 range of values \by Chi Square test

91
 92 To investigate if the reduced severity of clinical disease in recurrent infections could be
 93 correlated with a reduction in parasite burden, the Cq values of sub-clinical and diarrheal
 94 disease were measured (Table 2). The slopes derived from the GEE models for sub-clinical (1.9
 95 ± 0.2) and diarrheal (1.49 ± 0.31) infections were not significantly different from each other (Fig.
 96 S4). However recurrent infections had as expected a lower amount or burden of
 97 *Cryptosporidium* than did the first infection (slope -1.85 ± 0.21; p<0.0001) (Fig 2A).

98 **Table 2. Distribution and Clinical Characterization of repeated *Cryptosporidium***
 99 **infections**

| # of Infections | # of Children | Cryptosporidium infections | | | | | | | | | | | | Total # of infections |
|-----------------|---------------|----------------------------|-----------|-----------|------------|-----------|-----------|----------|-----------|-----|----------|-----|----------|-----------------------|
| | | 1st | | 2nd | | 3rd | | 4th | | 5th | | 6th | | |
| | | DS* | MS** | DS | MS | DS | MS | DS | MS | DS | MS | DS | MS | |
| 0 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 121 | 28 | 93 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 121 |
| 2 | 121 | 34 | 87 | 19 | 102 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 242 |
| 3 | 73 | 24 | 49 | 19 | 54 | 15 | 58 | 0 | 0 | 0 | 0 | 0 | 0 | 219 |
| 4 | 25 | 8 | 17 | 7 | 18 | 1 | 24 | 6 | 19 | 0 | 0 | 0 | 0 | 100 |
| 5 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 2 | 0 | 0 | 10 |
| 6 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 6 |
| Total | 392 | 96 | 247 | 46 | 176 | 17 | 84 | 6 | 22 | 0 | 3 | 0 | 1 | 698 |

100

101 **Fig 2 Parasite burden was lower in recurrent infections**

102 **A)** Correlation between parasite burden and the number of *Cryptosporidium* infections. Each
103 symbol represents the first detectable sample of an individual infection. Y-axis represents the
104 quantitative cycle (Cq) of the diagnostic pan-*Cryptosporidium* PCR assay. X-axis shows the
105 number of *Cryptosporidium* infections that had occurred in this child. The line represents the
106 slope (-1.85 ± 0.21) and Y-intercept (26.95 ± 0.44) estimated from the GEE model with the
107 exchangeable correlation structure ($p < 0.0001$)

108 **B)** Comparison of single infections (black symbol) with those that are part of a series (gray
109 symbol). Bar graph (indicating data mean \pm standard deviation) with individual data points. Each
110 symbol on the box plot represents the first positive sample of an individual infection. X-axis
111 refers to Infection number and, if the first infection, whether a second *Cryptosporidium* infection
112 took place in the 3 years of life. Y-axis represents the quantitative cycle (Cq) of the diagnostic
113 pan-*Cryptosporidium* PCR assay. Horizontal bars represent the result of a non-parametric
114 Kruskal-Wallis test **** indicates $p < 0.0001$

115

116 To investigate if an initial high burden infection provided better protection against future
117 infections with the *Cryptosporidium* parasite, we compared the Cq values of the infections in
118 children who only had one infection in the first three years of life vs the Cq values of the first
119 infection in children that had repeated infections (Fig 2B). The mean Cq values were similar in
120 both cases (single infections: Cq 27.6 ± 5.4 : 1st infection of multiples: 28.8 ± 6.0) and
121 significantly lower than that in subsequent second infections where infections were >1 (Cq
122 second infection: 31.5 ± 4.9).

123 We next evaluated if the lower parasite burden in repeat infections was influenced by the age of
124 the children. As most recurrent *Cryptosporidium* infections occurred in older children, (Table 1)
125 we analyzed a subset of the *Cryptosporidium* positive samples corresponding to the first to fifth

126 infections in children aged between 2.25 and 2.75 years. The parasite burden measured by
127 qPCR remained significantly lower in the recurrent infections (Fig 3). The negative relationship
128 of lower parasite burden with repeated infections was not an artefact of PCR inhibitors in the
129 stool of older children because detection of the Phocine herpesvirus (PhHV) DNA included as
130 internal extraction control [29] was not significantly affected by the number of prior
131 *Cryptosporidium* infections. We concluded that repeat infections had a lower parasite burden.

132

133 **Fig 3 Parasite burden in older children**

134 The amount of parasite in stool was determined as a function of the number of *Cryptosporidium*
135 infections in a child by linear regression. The analysis was restricted to children between 2.25 and
136 2.75 years of age (n=140). Each symbol represents the first detectable sample of an individual
137 infection. Y-axis, quantitative cycle of the diagnostic pan-Cryptosporidium PCR assay (Cq). X-
138 axis, the number *Cryptosporidium* infections that had occurred in each child. Slope: -1.65, R
139 squared value: 0.01125, Significance $p < 0.0001$.

140

141

142 The duration of diarrheal disease was similar in the first infection and later reinfections (single
143 infection: 4.8 ± 2.9 days; primary infection: 5.5 ± 3.9 days; later infections: 5.2 ± 3.6 days),
144 however, the proportion of the diarrhea-associated *Cryptosporidium* infections decreased in the
145 recurrent infections (Chi-squared test for trend $p = 0.011$) (Table 1). We concluded that the
146 repeated *Cryptosporidium* infections were more likely to be sub-clinical.

147

148 ***Cryptosporidium* and growth faltering**

149 Growth faltering (low height for age; HAZ score) was analyzed from the 3 year old children
150 based on the number of *Cryptosporidium spp.* infections [0 - 3 years] (both diarrhea and sub-

151 clinical) (Table 2, Fig S5 & 6). The association between cryptosporidiosis and HAZ score at
152 three years was examined by multiple regression in order to account for the effect of the
153 confounding variables previously identified (Table 3) [13,21].

154
155 **Table 3 Regression Analysis using selected predictors to test the association of**
156 **Cryptosporidiosis with Height-for-Age Scores at 3 Years**

| Parameter | Effect (95% Confidence Interval) | P Value |
|----------------------------|----------------------------------|---------|
| Cryptosporidium Infections | -0.12 (-0.197, -0.043) | 0.0024 |
| Child LAZ at Birth | 0.252 (0.159, 0.345) | <0.0001 |
| Maternal Weight | 0.017 (0.007, 0.027) | 0.0011 |
| Maternal Height | 0.037 (0.018, 0.055) | <0.0001 |
| Maternal Education | 0.237 (0.027, 0.448) | 0.0273 |
| Household income | 0.001 (0.000, 0.002) | 0.1527 |
| Treated water | 0.163 (-0.045, 0.371) | 0.1234 |

158
159 *Cryptosporidium* infection was negatively associated with the HAZ score at 3 years after
160 adjusting for birth length-for-age (LAZ) score and maternal weight and education: each
161 *Cryptosporidium* infection reoccurrence resulted in a decrease in HAZ score (Δ 0.12) at 3 years
162 (Table 5). No significant relation was found between malnutrition at birth (LAZ score) and total
163 number of *Cryptosporidium* infections during the follow-up (Fig 4A). However, the total number
164 of *Cryptosporidium* infections was negatively associated with HAZ score at 3 years (Fig 4B,
165 regression coef=-0.152, p=0.0004) The association between HAZ and *Cryptosporidium spp.*
166 infections was unaffected by whether the event was a sub-clinical infection or diarrheal disease
167 (Fig S7).

168 **Fig 4 Cryptosporidiosis frequency was associated with growth faltering distinct from the**
169 **impact of birth nutritional status**

170 A) Relationship between length for age z score (LAZ) at birth (Y-axis) and the total number of
171 *Cryptosporidium spp.* infections (X-axis). The slope was not significantly different from one.

172 B) Relationship between height for age z score (HAZ) at 3 years (Y-axis) and the total number
173 of *Cryptosporidium spp.* infections (X-axis). Slope: -0.152 ± 0.0429 , R squared value: 0.0313,
174 Significance $p=0.0004$. Children were defined to be at risk for growth faltering with a LAZ or
175 HAZ score <-1 and malnourished at LAZ or HAZ score <-2 . Orange box: birth LAZ or 3 year
176 HAZ score -1 to -2 ; red box: birth LAZ or 3 year HAZ or score <-2 .

177
178 Other measurements that are used as indicators of malnutrition were also significantly
179 associated with the number of *Cryptosporidium* infections. These included mid-upper arm
180 circumference (MUAC) (Fig S8A; MUACZ vs. number of *Cryptosporidium* infections slope: -
181 0.088; $p=0.0123$ and weight-for-age (WAZ score) (Fig S8B) (linear regression analysis slope: -
182 0.115 $p=0.0093$). However, neither BAZ (body-mass- for- age) (Fig S8C), used to measure
183 acute protein-energy malnutrition or wasting (WHZ) were affected by a history of
184 *Cryptosporidium* infections (Fig S8D).

185 The Pearson correlations among the number of *Cryptosporidium* infections, LAZ at birth,
186 diarrheal episodes and HAZ at year 3 are shown in Fig 5A (*Cryptosporidium* infections: HAZ at
187 year 3: coef = -0.18 , $p=0.024$; *Cryptosporidium* infections: diarrheal episodes captured (all
188 causes): coef = 0.22 , $p>0.0001$; HAZ at year 3: LAZ at birth: coef = 0.28 , $p= 0.008$). As
189 expected, a significant correlation existed between LAZ at birth and HAZ at year 3 (simple linear
190 regression $p<0.0001$ Fig 5B).

191 Enteric pathogens are endemic in the Bangladesh study population [30] and as a consequence,
192 infants enrolled in the study cohort had repeated diarrheal episodes of which only some were
193 associated with infection with the *Cryptosporidium* parasite. However, while *Cryptosporidium*
194 infections (diarrheal and sub-clinical) were significantly associated with child HAZ at year 3
195 (Pearson's correlation $p=0.0004$), the number of all-cause diarrheal episodes was not (Fig 5C;
196 S2 Table 3). This result supported our conclusion that this growth shortfall was specifically
197 associated with recurrent cryptosporidiosis.

198

199 **Fig 5 Correlates of cryptosporidiosis-associated growth-faltering**

200 A) Correlation matrix of cryptosporidiosis, all-cause diarrhea, LAZ at birth and HAZ at 3 years,
201 calculated using Pearson r. Bar on the right indicates strength and direction of association. B)
202 Comparison of three year-HAZ with birth LAZ. (Slope: -0.294 ± 0.05 ; R squared value: 0.08;
203 Significance $p < 0.0001$). C) Relationship of all-cause diarrhea with HAZ at 3 years of age ($p =$
204 NS).

205 **Mucosal IgA against the sporozoite Cp23 protein was associated with protection from**
206 **growth faltering**

207 In previous work it was shown in this cohort that a high level ($>$ mean value) of fecal anti-Cp23
208 IgA at one year of age was associated with an increased resistance to cryptosporidiosis through
209 age three [14,20]. Here we additionally discovered that children with high levels (upper 50th
210 percentile) of fecal anti-Cp23 IgA at one year of age were protected from growth faltering
211 through year 3 (Fig 6). Subgrouping the children into Group 2a (never infected by evidence of
212 anti-Cp23 IgA levels and diagnostic qPCR assays; $n=20$) and Group 2b (diagnostic qPCR
213 positive only; $n=185$) versus Group 1 children with high levels of IgA at one year ($n=171$) did not
214 alter the association with growth faltering (Fig S9A). Analysis of the fecal IgA antibodies against
215 a second sporozoite peptide (Cp17) was also performed. Although a similar trend was observed
216 the difference in year 3 HAZ was not significantly different (Fig S9B). A high level of fecal anti-
217 Cp23 at one year was not associated with any drop in the parasite burden at the next
218 *Cryptosporidium* infection (first subsequent new infection: Cq of IgA high responders 28.2 ± 5.6
219 versus 27.6 ± 5.6 $p=0.43$).

220

221 **Fig 6 High anti-Cp23 IgA levels were associated with a reduction in cryptosporidiosis-**
222 **associated growth-faltering.**

223 Group 1 and 2 children were in the upper and lower 50th percentile for fecal IgA anti-Cp23
224 respectively. HAZ are shown for children in both year one and year three of life. Mean \pm
225 standard deviation with individual data points. Horizontal bars represent the result of a non-
226 parametric Kruskal-Wallis test *** $p < 0.001$, ** $p < 0.01$

227 **Discussion**

228 The key finding of this paper is that naturally acquired immunity protects from *Cryptosporidium*
229 diarrhea but does not provide sterilizing immunity. The importance of this observation is two-
230 fold: first it indicates that transmission likely occurs in semi-immune populations; and second
231 that continued sub-clinical infections increase the risk of infection-related growth faltering.
232 Encouragingly however, acquired immunity associated with high levels of mucosal IgA against
233 the Cp23 cryptosporidium sporozoite antigen were associated with protection from malnutrition.
234

235 Many previous studies on cryptosporidiosis have focused on the health impact of diarrhea-
236 associated cryptosporidiosis [7,12,31–34]. However sub-clinical disease, as opposed to
237 infection accompanied by diarrhea, may also have long term effects on child health. The link
238 between sub-clinical cryptosporidiosis and malnutrition is now well known if not yet well
239 understood [8,9,13,32]. In a recent study the global prevalence of cryptosporidiosis in people
240 without diarrheal symptoms was 4.4% (95% confidence interval 2.9 - 6.3)[35]. During the 3
241 years of this study 212 children (54%) had only sub-clinical *Cryptosporidium* infections. This
242 longitudinal study allowed us to take an in depth look at the role of sub-clinical reinfections in the
243 exacerbation of growth faltering [13,22,25].

244 Anthropometric measurements are reliable non-invasive methods to monitor child malnutrition.
245 The most commonly used metrics are a shortfall in child growth (low height for age: HAZ score)
246 a consequence of chronic undernutrition and wasting (exemplified by a low weight for height:

247 WHZ score). In line with most studies our results show that a history of cryptosporidiosis was
248 associated with a decrease in the HAZ score of children irrespective of infection severity
249 [8,26,36,37] . Here we found that child growth was negatively impacted not only by the first
250 episode of cryptosporidiosis, but both occurred and remained constant in succeeding infections,
251 even though parasite burden and diarrheal disease decreased. This study has, therefore, shown
252 that naturally acquired partial immunity was not effective at preventing growth faltering and that
253 a control strategy focused on only preventing diarrheal cryptosporidiosis may not prevent the
254 stunted growth associated with cryptosporidiosis.

255 A limitation of the current study is that it was not possible to unambiguously attribute an episode
256 of diarrhea to *Cryptosporidium* because children in this community were infected with multiple
257 enteropathogens at the same time [26,30]. To mitigate the problem of correctly identifying
258 *Cryptosporidium*-associated diarrheal infections these were defined as an episode of diarrhea
259 accompanied by a new *Cryptosporidium* infection (i.e. the immediately preceding surveillance or
260 diarrheal stool sample was negative for *Cryptosporidium*) [13]. A second limitation was that
261 surveillance stool samples were collected at only monthly intervals which likely missed some
262 subclinical infections, potentially underestimating the impact of cryptosporidiosis on child
263 growth. The study however had notable strengths including most importantly its longitudinal
264 design that combined collection of surveillance and clinical specimens with studies on child
265 growth faltering.

266 The association of mucosal immunity to Cp23 with protection from growth faltering offers hope
267 that a cryptosporidiosis vaccine could have a measurable impact on child health, even in the
268 absence of absolute protection from infection.

269

270 **Acknowledgement**

271 We are grateful for the participation of the parents and children in this study as well as the staff of
272 the Emerging Infectious Diseases Division of icddr,b for contributing to this research.

273 **Author Contributions**

274 CG, MK, RH and WP designed, and RH, WP, MA, JAW, CG and MK drafted the study protocols
275 and WP directed the work described in this paper. MK, TA, BH, RT and AK acquired the data
276 used in this manuscript. UN curated the study data. UN, JM, MK and CG analyzed the study data.
277 CG wrote the first draft of the manuscript that was reviewed and amended by all the authors who
278 also approved the final manuscript.

279 **Methods**

280 **Child cohort**

281 A total of 500 children were enrolled within one week of birth in an urban slum of Dhaka,
282 Bangladesh beginning in June 2014 through March 2016 and were monitored for diarrheal
283 diseases through bi-weekly home visits by trained field investigators. A monthly stool sample
284 was also collected to evaluate asymptomatic infection and growth was measured every 3
285 months (“Cryptosporidiosis and Enteropathogens in Bangladesh”; ClinicalTrials.gov identifier
286 NCT02764918). This area (Section 11 of Mirpur Thana) is densely populated with participants in
287 this study having an average of 5.5 people living in 1.6 rooms. Annual median household
288 income of participants was 14,000 Taka or approximately US \$164 (Table 4). Anthropometric
289 data was collected as previously described [13]. Each child was weighed on an electronic scale
290 (kilograms, measured with electronic scale; TANITA, HD-314). Child height or length
291 (depending on age) and mid-upper arm circumference were measured to the nearest 0.1 cm
292 using a measuring board and plastic tape (Table 5). The height-for-age z score (HAZ); weight

293 for age z score (WAZ); weight for height (WHZ); body mass index for age (BAZ); and mid-upper
 294 arm circumference for age (MUACZ) were calculated using the World Health Organization
 295 Anthro software (version 3.2.2) [13]. Children who had a HAZ score <-1 were defined as 'at risk
 296 for malnutrition' and HAZ < -2 as malnourished [27,28]. Diarrhea was defined as ≥3 loose
 297 stools within a 24-hour period as reported by the child's caregiver with episodes separated by a
 298 gap of at least 3 days. This paper reports the data from 392 infants who were followed through
 299 three years of age.

300 **Table 4 Maternal and family demographics**

| Maternal and Family Characteristics | N=392 |
|--|-----------------|
| Mean Maternal Age, year (SD) | 24.63 (4.68) |
| Mean Maternal Weight, Kg (SD) | 51.82 (10.17) |
| Mean Maternal Height, Cm (SD) | 149.71 (5.03) |
| Mean Maternal BMI, kg/m ² (SD) | 23.10 (4.32) |
| No Maternal Education, N (%) | 87 (22.2) |
| Median Household income (BDT*) (IQR) | 14,000 (10,000) |
| Treated water (Boil), N (%) | 390 (74.0) |

301 **Abbreviations:** SD, Standard Deviation; BDT, Bangladesh Taka; IQR, Inter
 302 Quartile Range

303 *1000 BDT is approximately 12 US dollars

304

305

306 **Table 5 Infant demographic characteristics**

307

| Infant Demographic Characteristics | Year 2 N=421 | Year 3 N=392 |
|---|-------------------------|-------------------------|
| Gender, Female N (%) | 229 (54.4) | 214 (54.6) |
| Mean Infant Age in days, Range | 733 (719 - 783) | 1099 (1035 - 1134) |
| Mean Weight, Kg, (SD) | 10.17 (1.31) | 11.93 (1.52) |
| Mean Height, Cm, (SD) | 81.72 (3.18) | 89.78 (3.74) |
| Mean MUAC, Cm, (SD) | 14.87 (1.02) | 15.3 (1.00) |
| Mean WAZ, (SD) | -1.34 (1.05) | -1.42 (0.99) |
| Mean HAZ, (SD) | -1.56 (0.98) | -1.54 (0.98) |
| Mean MUACZ, (SD) | -0.15 (0.85) | -0.34 (0.79) |

| | | |
|----------------|--------------|--------------|
| Mean BAZ, (SD) | -0.52 (0.98) | -0.63 (0.91) |
|----------------|--------------|--------------|

308 **Abbreviations:** SD, Standard Deviation, MUAC, Mid Upper Arm Circumference, WAZ, Weight-
309 for-age, HAZ, Height-for-age, MUACZ, Mid Upper Arm Circumference-for-age, BAZ, body mass
310 index-for-age
311

312 **Ethics Statement**

313 The study was approved by the Ethical and Research Review Committees of the International
314 Centre for Diarrhoeal Disease Research, Bangladesh (PR-13092) and by the Institutional
315 Review Board of the University of Virginia (IRB#20388) . Informed written consent was obtained
316 from the parents or guardians for the participation of the subjects in the study.

317 **Sampling and specimen testing**

318
319 Fresh stool samples collected in the field were placed on ice and then brought to the lab on the
320 same day and frozen within 6 h of collection (Fig S1). Stool specimens were collected from
321 children every month (monthly surveillance) and during episodes of diarrhea. A modified
322 Qiagen stool DNA extraction protocol with 95°C incubation and a 3-minutes bead-beating step
323 was used to extract DNA [13](Fig S2). These samples were tested with a multiplex qPCR
324 assay which utilizes pan-Cryptosporidium primers and probes targeting the 18S rDNA gene and
325 primers and probes to detect the Phocine herpesvirus (PhHV) extraction control (obtained from
326 the European Virus Archive Global organization) as previously described (Fig S3). All samples
327 with a cycle threshold of ≤ 40 for cryptosporidium were used in this analysis [13]. In year 3 the
328 diagnostic qPCR assay was not able to be completed on 0.9% of the collected diarrheal and
329 4.6% of the monthly surveillance samples (Table S1).

330 Infection with *Cryptosporidium* was defined as detection of *Cryptosporidium* DNA by qPCR from
331 stool. PCR- positive samples were classified as a separate infection if occurring greater than 65
332 days after the preceding positive sample [13]. The *Cryptosporidium* infection phenotype

333 (diarrheal or sub-clinical) was based upon symptoms at the time of detection of the first
334 *Cryptosporidium* - positive stool sample, whether diarrheal stool or monthly surveillance.

335 **Statistical analysis**

336 Descriptive statistics were expressed in mean \pm standard deviation for continuous variables and
337 as frequencies and proportions for categorical variables. The frequency of repeated
338 *Cryptosporidium* infections in the first 3 years of life was summarized for diarrhea and sub-
339 clinical infections separately and their differences were evaluated with the χ^2 test. To account for
340 within-child correlations among repeated *Cryptosporidium* infections, the relationship between
341 parasite burden and the number of repeated *Cryptosporidium* infections was evaluated using
342 the Generalized Estimating Equation (GEE) for repeated measurements, assuming an
343 exchangeable correlation structure. Pearson correlation was calculated for univariate
344 association of individual predictors with HAZ at 3 years. Since confounders such as LAZ at birth,
345 maternal weight and height, maternal education, household income and access to treated water
346 were previously shown to impact HAZ [8,13], a multivariable linear regression was performed to
347 evaluate the association between *Cryptosporidium* infection and HAZ at 3 years after adjusting
348 for these factors (Table 3). Similarly, a multiple regression analysis was performed to
349 independently evaluate whether the number of episodes of diarrhea, irrespective of the
350 causative pathogen, was associated with HAZ at 3 years. Analyses were performed using both
351 the GraphPad Prism version 8.4.3 for Mac, (GraphPad Software, San Diego, California USA,),
352 SAS 9.4 (Raleigh, NC) and R version 3.3.3, 32-bit.

353

354

355 **Funding**

356 This work was supported by grants NIH R01-043596 to WP and CG, R21-142656 to CG and the
357 Bill & Melinda Gates Foundation OPP1100514 to WP. The governments of Bangladesh,
358 Canada, Sweden, and the UK provide core support to icddr,b. The funders had no role in study
359 design, data collection and analysis or decision to submit for publication.

360

361

362 References

- 363 1. Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. The Burden of
364 Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in
365 Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data
366 from the Global Enteric Multicenter Study (GEMS). Kosek M, editor. PLoS Negl Trop Dis.
367 2016;10: e0004729. doi:10.1371/journal.pntd.0004729
- 368 2. Wang H, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global,
369 regional, and national under-5 mortality, adult mortality, age-specific mortality, and life
370 expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study
371 2016. Lancet. 2017;390: 1084–1150. doi:10.1016/S0140-6736(17)31833-0
- 372 3. Korpe PS, Valencia C, Haque R, Mahfuz M, McGrath M, Houpt E, et al. Epidemiology
373 and Risk Factors for Cryptosporidiosis in Children from Eight Low-income Sites: Results
374 from the MAL-ED Study. Clin Infect Dis. 2018; doi:10.1093/cid/ciy355
- 375 4. Haque R, Mondal D, Karim A, Molla IH, Rahim A, Faruque ASG, et al. Prospective case-
376 control study of the association between common enteric protozoal parasites and
377 diarrhea in Bangladesh. Clin Infect Dis. 2009;48: 1191–1197. doi:10.1086/597580
- 378 5. Cama V a, Ross JM, Crawford S, Kawai V, Chavez-Valdez R, Vargas D, et al.
379 Differences in clinical manifestations among Cryptosporidium species and subtypes in
380 HIV-infected persons. J Infect Dis. 2007;196: 684–91. doi:10.1086/519842
- 381 6. Chalmers RM, Davies AP, Tyler K. Cryptosporidium. Microbiol (United Kingdom).
382 2019;165: 500–502. doi:10.1099/mic.0.000764
- 383 7. Chavez MA, White AC. Novel treatment strategies and drugs in development for
384 cryptosporidiosis. Expert Review of Anti-Infective Therapy. Taylor and Francis Ltd; 2018.
385 pp. 655–661. doi:10.1080/14787210.2018.1500457
- 386 8. Korpe P, Haque R, Gilchrist CA, Valencia C, Niu F, Lu MM, et al. Natural History of
387 Cryptosporidiosis in a Longitudinal Study of Slum-Dwelling Bangladeshi Children:
388 Association with Severe Malnutrition. PLoS Negl Trop Dis. 2016;10: e0004564.
389 doi:10.1371/journal.pntd.0004564
- 390 9. Kattula D, Jeyavelu N, Prabhakaran AD, Premkumar PS, Velusamy V, Venugopal S, et
391 al. Natural History of Cryptosporidiosis in a Birth Cohort in Southern India. Clin Infect Dis.
392 2017;64: 347–354. doi:10.1093/cid/ciw730
- 393 10. Khalil IA, Troeger C, Rao PC, Blacker BF, Brown A, Brewer TG, et al. Morbidity, mortality,
394 and long-term consequences associated with diarrhoea from Cryptosporidium infection in
395 children younger than 5 years: a meta-analyses study. Lancet Glob Heal. 2018;6: e758–
396 e768. doi:10.1016/S2214-109X(18)30283-3

- 397 11. Krumkamp R, Aldrich C, Maiga-Ascofare O, J M, Rakotozandrindrainy N, Borrmann S, et
398 al. Transmission of *Cryptosporidium* spp. among human and animal local contact
399 networks in sub-Saharan Africa: a multi-country study. *Clin Infect Dis*. 2020; ciaa223.
400 Available: <https://pubmed.ncbi.nlm.nih.gov/32150243/>
- 401 12. Eibach D, Krumkamp R, Al-Emran HM, Sarpong N, Hagen RM, Adu-Sarkodie Y, et al.
402 Molecular characterization of *Cryptosporidium* spp. among children in rural Ghana. *PLoS*
403 *Negl Trop Dis*. 2015;9: e0003551. doi:10.1371/journal.pntd.0003551
- 404 13. Steiner KL, Ahmed S, Gilchrist CA, Burkey C, Cook H, Ma JZ, et al. Species of
405 *Cryptosporidia* Causing Subclinical Infection Associated With Growth Faltering in Rural
406 and Urban Bangladesh: A Birth Cohort Study. *Clin Infect Dis*. 2018;67: 1347–1355.
407 doi:10.1093/cid/ciy310
- 408 14. Steiner KL, Kabir M, Hossain B, Gilchrist CA, Ma JZ, Ahmed T, et al. Delayed Time to
409 *Cryptosporidiosis* in Bangladeshi Children is Associated with Greater Fecal IgA against
410 Two Sporozoite-Expressed Antigens. *Am J Trop Med Hyg*. 2021;104: 229–232.
411 doi:10.4269/ajtmh.20-0657
- 412 15. Taniuchi M, Sobuz SU, Begum S, Platts-Mills JA, Liu J, Yang Z, et al. Etiology of
413 Diarrhea in Bangladeshi Infants in the First Year of Life Using Molecular Methods. *J Infect*
414 *Dis*. 2013;e-pub ahea: jit507-. doi:10.1093/infdis/jit507
- 415 16. Lemieux MW, Sonzogni-Desautels K, Ndao M. Lessons learned from protective immune
416 responses to optimize vaccines against cryptosporidiosis [Internet]. *Pathogens*. MDPI
417 AG; 2018. doi:10.3390/pathogens7010002
- 418 17. Sateriale A, Šlapeta J, Baptista R, Engiles JB, Gullicksrud JA, Herbert GT, et al. A
419 Genetically Tractable, Natural Mouse Model of *Cryptosporidiosis* Offers Insights into Host
420 Protective Immunity. *Cell Host Microbe*. 2019;26: 135-146.e5.
421 doi:10.1016/j.chom.2019.05.006
- 422 18. Checkley W, White AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen X-MM, et al. A
423 review of the global burden, novel diagnostics, therapeutics, and vaccine targets for
424 *cryptosporidium*. *Lancet Infect Dis*. 2015;15: 85–94. doi:10.1016/S1473-3099(14)70772-8
- 425 19. Tzipori S, Robertson D, Chapman C. Remission of diarrhoea due to cryptosporidiosis in an
426 immunodeficient child treated with hyperimmune bovine colostrum. *Br Med J* . 1986;293:
427 1276–7. Available:
428 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1342109&tool=pmcentrez&ren](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1342109&tool=pmcentrez&rendertype=abstract)
429 [dertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1342109&tool=pmcentrez&rendertype=abstract)
- 430 20. Steiner KL, Kabir M, Priest JW, Hossain B, Gilchrist CA, Cook H, et al. Fecal IgA against
431 a sporozoite antigen at 12 months is associated with delayed time to subsequent
432 cryptosporidiosis in urban Bangladesh: a prospective cohort study. *Clin Infect Dis*. 2019;

- 433 doi:10.1093/cid/ciz430
- 434 21. Steiner KL, Kabir M, Priest JW, Hossain B, Gilchrist CA, Cook H, et al. Fecal
435 immunoglobulin a against a sporozoite antigen at 12 months is associated with delayed
436 time to subsequent cryptosporidiosis in urban Bangladesh: A prospective cohort study.
437 Clin Infect Dis. 2020;70: 323–326. doi:10.1093/cid/ciz430
- 438 22. Ajjampur SSR, Sarkar R, Sankaran P, Kannan A, Menon VK, Muliyl J, et al. Symptomatic
439 and asymptomatic *Cryptosporidium* infections in children in a semi-urban slum
440 community in southern India. Am J Trop Med Hyg. 2010;83: 1110–5.
441 doi:10.4269/ajtmh.2010.09-0644
- 442 23. Okhuysen PC, Chappell CL, Sterling CR, Jakubowski W, DuPont HL. Susceptibility and
443 serologic response of healthy adults to reinfection with *Cryptosporidium parvum*. Infect
444 Immun. 1998;66: 441–443. doi:10.1128/iai.66.2.441-443.1998
- 445 24. Guerrant DI, Moore SR, Lima AAM, Patrick PD, Schorling JB, Guerrant RL. Association
446 of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and
447 cognitive function four-seven years later in a poor urban community in northeast Brazil.
448 Am J Trop Med Hyg. 1999;61: 707–713. doi:10.4269/ajtmh.1999.61.707
- 449 25. Checkley W, Gilman RH, Epstein LD, Suarez M, Diaz JF, Cabrera L, et al. Asymptomatic
450 and symptomatic cryptosporidiosis: their acute effect on weight gain in Peruvian children.
451 Am J Epidemiol. 1997;145: 156–63. doi:10.1093/oxfordjournals.aje.a009086
- 452 26. Schnee AE, Haque R, Taniuchi M, Uddin J, Alam M, Liu J, et al. Identification of etiology-
453 specific diarrhea associated with linear growth faltering in Bangladeshi infants. Am J
454 Epidemiol. 2018;187: 2210–2218. doi:10.1093/aje/kwy106
- 455 27. de Onis M, Branca F. Childhood stunting: A global perspective. Matern Child Nutr.
456 2016;12: 12–26. doi:10.1111/mcn.12231
- 457 28. Guide I. Interpretation Guide. Nutr Landcape Inf Syst. 2012; 1–51.
458 doi:10.1159/000362780.Interpretation
- 459 29. Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of quantitative
460 molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of
461 the GEMS case-control study. Lancet. 2016;388: 1291–1301. doi:10.1016/S0140-
462 6736(16)31529-X
- 463 30. Taniuchi M, Sobuz SU, Begum S, Platts-Mills JA, Liu J, Yang Z, et al. Etiology of diarrhea
464 in Bangladeshi infants in the first year of life analyzed using molecular methods. J Infect
465 Dis. 2013;208: 1794–802. doi:10.1093/infdis/jit507

- 466 31. Platts-Mills JA, Liu J RE et al. Aetiology, burden and clinical characteristics of diarrhea in
467 children in low-resource settings using quantitative molecular diagnostics: results from
468 the MAL-ED cohort study. *Lancet Glob Heal*. 2018;in press.
- 469 32. Cama VA, Bern C, Roberts J, Cabrera L, Sterling CR, Ortega Y, et al. *Cryptosporidium*
470 species and subtypes and clinical manifestations in children, Peru. *Emerg Infect Dis*.
471 2008;14: 1567–74. doi:10.3201/eid1410.071273
- 472 33. Chappell CL, Okhuysen PC, Langer-Curry RC, Akiyoshi DE, Widmer G, Tzipori S.
473 *Cryptosporidium meleagridis*: Infectivity in healthy adult volunteers. *Am J Trop Med Hyg*.
474 2011;85: 238–242. doi:10.4269/ajtmh.2011.10-0664
- 475 34. Ajjampur SSR, Liakath FB, Kannan A, Rajendran P, Sarkar R, Moses PD, et al. Multisite
476 study of cryptosporidiosis in children with diarrhea in India. *J Clin Microbiol*. 2010;48:
477 2075–81. doi:10.1128/JCM.02509-09
- 478 35. Dong S, Yang Y, Wang Y, Yang D, Yang Y, Shi Y, et al. Prevalence of *Cryptosporidium*
479 Infection in the Global Population: A Systematic Review and Meta-analysis. *Acta*
480 *Parasitol*. 2020; doi:10.2478/s11686-020-00230-1
- 481 36. Hossain MJ, Saha D, Antonio M, Nasrin D, Blackwelder WC, Ikumapayi UN, et al.
482 *Cryptosporidium* infection in rural Gambian children: Epidemiology and risk factors.
483 Bartelt LA, editor. *PLoS Negl Trop Dis*. 2019;13: e0007607.
484 doi:10.1371/journal.pntd.0007607
- 485 37. Bushen OY, Kohli A, Pinkerton RC, Dupnik K, Newman RD, Sears CL, et al. Heavy
486 cryptosporidial infections in children in northeast Brazil: comparison of *Cryptosporidium*
487 *hominis* and *Cryptosporidium parvum*. *Trans R Soc Trop Med Hyg*. 2007;101: 378–84.
488 doi:10.1016/j.trstmh.2006.06.005

489

490

491 **Supplemental Figures and Tables**

492

493 Table S1. **Symptomatic and asymptomatic samples collected during year 3**

494

495 Table S2. **Multivariable analysis of total all cause diarrhea and HAZ at year 3**

496

497 Fig S1. **Flow chart of stool processing and molecular testing**

498

499 Fig S2. **Flow chart of stool TNA extraction procedure using QIAamp Fast DNA Stool Mini Kit from fresh or frozen stool samples.**

500

501 Fig S3. **Flow chart of Multiplex qPCR of *Cryptosporidium*, *Giardia*, *Entamoeba histolytica* by targeting the 18S gene**

502

503 Fig S4. **Parasite Burden in diarrheal and sub-clinical infections**

504

505 Relationship between Parasite Burden and the number of recurrent *Cryptosporidium* infections. Each symbol represents the first detectable sample of an individual infection. Y-axis, quantitative cycle of the diagnostic pan-*Cryptosporidium* PCR assay (Cq). X-axis, the total number of *Cryptosporidium* infections. The infection was designated as either diarrheal (red) or sub-clinical (green) based on the current infection phenotype. The data from diarrheal cases was offset to improve data visualization. To account for within-child correlations among repeated *Cryptosporidium* infections, the generalized estimating equation (GEE) method for repeated measurements were used with exchangeable correlation structure. As the intercept of the diarrheal and sub-clinical models was not statistically different the common intercept (27.02 ± 0.45) was used. The slope of the data derived from the sub-clinical (1.9 ± 0.2) and diarrheal (1.49 ± 0.31) exchangeable models were not significantly different from each other ($p=0.071$) although both were statistically different from zero ($p<0.0001$).

518

519 Fig S5. **Distribution of repeated *Cryptosporidium* infections**

520

521 x axis child age in months; left y-axis child HAZ scores; right y-axis frequency of *Cryptosporidium* (diarrheal and sub-clinical) infections (shown as the number that occurred per the age of the child in months). All graphs include as a reference the HAZ score of children where no *Cryptosporidium* infections were detected (green circle and line). *Cryptosporidium* infections: Light blue triangle dotted blue connection line: infection one; purple circle and dotted line: infection two; light red square and dotted line: infection three; black triangle and dotted line: infection four A) blue symbol and solid line HAZ score of children who had one *Cryptosporidium* infections by 3 years of age B) purple square and solid line HAZ score of children who had two *Cryptosporidium* infections by three years of age C) red square and solid line HAZ score of children who had three *Cryptosporidium* infections by three years of age D) black square and solid line HAZ score of children who had four *Cryptosporidium* infections by three years of age

531

532

533 Fig S6. **Recurrent cryptosporidiosis results in greater growth faltering** Each symbol represents a single child. Box plot comparing the height for age z score at 3 years (HAZ) (Y-axis) mean and standard deviation shown Children were considered to be at Risk for malnutrition if they have a HAZ score <-1 and malnourished at HAZ-2: orange box: 3-year HAZ score -1 to -2 ; red box 3-year HAZ score <-2 . X-axis Number of *Cryptosporidium* infections. Bar

537

538 indicates the result of a non-parametric Kruskal-Wallis test for multiple comparisons * indicates
539 $p < 0.05$ ** indicates $p < 0.01$

540

541

542 **Fig S7. Comparison of Cryptosporidiosis associated Growth-faltering in diarrheal and**
543 **sub-clinical infections**

544 Graphs show results from a simple linear regression with each symbol representing a single
545 child. Black symbols represent children who were never infected or had sub-clinical infections.
546 The blue symbols indicate children who have had one or more than one episodes of diarrhea-
547 associated cryptosporidiosis. Height for age (HAZ) z score at 3 years is shown on the Y-axis.
548 The slope of the diarrheal-associated and sub-clinical groups are identical. Pooled Slope: -
549 0.1545. Children are considered to be at Risk for malnutrition if they have a HAZ score < -1 and
550 malnourished at HAZ -2 : orange box: 3-year HAZ score -1 to -2 ; red box: 3-year HAZ score $< -$
551 2 . X-axis indicates number of *Cryptosporidium* infections

552

553 **Fig S8. Cryptosporidiosis was associated with chronic but not acute malnutrition at year**
554 **3**

555 Graphs show results from a simple linear regression with each symbol representing a single
556 child X-axis indicates number of *Cryptosporidium* infections A) Y-axis MUACZ circumference of
557 the mid-upper arm (muscle wasting) B) Y-axis WHZ score (low weight for height (wasting) a
558 measure of acute malnutrition C) Y axis WAZ score (low weight for age) a measure of acute and
559 chronic malnutrition and D) BAZ (body mass index for age)


560

561

562

563

564 **Fig 1 COHORT diagram.** Study subjects, collected samples and new infection numbers




565 Abbreviations: RT-QPCR quantitative polymerase chain reaction; DS: Diarrheal samples; FU:
 566 Follow-up; MS: Monthly Samples, Cq: Cycle Quantification


567

568 Fig 2

571 A



571 B




573 **Fig 2 Parasite burden was lower in recurrent infections**

574 **A)** Correlation between parasite burden and the number of *Cryptosporidium* infections. Each
575 symbol represents the first detectable sample of an individual infection. Y-axis represents the
576 quantitative cycle (Cq) of the diagnostic pan-Cryptosporidium PCR assay. X-axis shows the
577 number of *Cryptosporidium* infections that had occurred in this child. The line represents the
578 slope (-1.85 ± 0.21) and Y-intercept (26.95 ± 0.44) estimated from the GEE model with the
579 exchangeable correlation structure ($p < 0.0001$)

580 **B)** Comparison of single infections (black symbol) with those that are part of a series (gray
581 symbol). Bar graph (indicating data mean \pm standard deviation) with individual data points. Each
582 symbol on the box plot represents the first positive sample of an individual infection. X-axis

583 refers to Infection number and, if the first infection, whether a second *Cryptosporidium* infection
584 took place in the 3 years of life. Y-axis represents the quantitative cycle (Cq) of the diagnostic
585 pan-Cryptosporidium PCR assay. Horizontal bar represents the result of a non-parametric
586 Kruskal-Wallis test **** indicates $p < 0.0001$
587

588 Fig 3




589
590
591
592
593
594
595
596
597

Fig 3 Parasite burden in older children


The amount of parasite in stool as a function of the number of cryptosporidia infections in a given child by linear regression. The analysis was restricted to children between 2.25 and 2.75 years of age (n=140). Each symbol represents the first detectable sample of an individual infection. Y-axis, quantitative cycle of the diagnostic pan-Cryptosporidium PCR assay (Cq). X-axis, the number of *Cryptosporidium spp.* infections that had occurred in each child. Slope: -1.65, R squared value: 0.01125, Significance $p < 0.0001$.

598



599

600



601

602 **Fig 4 Cryptosporidiosis frequency was associated with growth faltering distinct from the**
603 **impact of birth nutritional status.**

604 A) Relationship between length for age z score (LAZ) at birth (Y-axis) and the total number of
605 *Cryptosporidium spp.* infections (X-axis). The slope was not significantly different from one.

606 B) Relationship between height for age z score (HAZ) at 3 years (Y-axis) and the total number
607 of *Cryptosporidium spp.* infections (X-axis). Slope: -0.152 ± 0.0429 , R squared value: 0.0313,

608 Significance $p=0.0004$. Children were defined to be at risk for growth faltering with a LAZ or
609 HAZ score <-1 and malnourished at LAZ or HAZ score <-2 . Orange box: birth LAZ or 3 year

610 HAZ score -1 to -2 ; red box: birth LAZ or 3 year HAZ or score <-2 .

611


612

613 **Fig 5 Correlates of cryptosporidiosis-associated growth-faltering**

614 A) Correlation matrix of cryptosporidiosis, all-cause diarrhea, LAZ at birth and HAZ at 3
615 years, calculated using Pearson r. Bar on the right indicates strength and direction of
616 association. B) Comparison of three year-HAZ with birth LAZ. (Slope: -0.294 ± 0.05 ; R
617 squared value: 0.08; Significance $p < 0.0001$) C) Relationship of all-cause diarrhea with
618 HAZ at 3 years of age ($p = \text{NS}$).
619


A


620
621



622
623
624

625
626






628

630 **Fig 6 High anti-Cp23 IgA levels were associated with a reduction in cryptosporidiosis-**
631 **associated growth-faltering.**

632 Group 1 and 2 children were in the upper and lower 50th percentile for fecal IgA anti-Cp23
633 respectively. HAZ are shown for children in both year one and year three of life. Mean \pm
634 standard deviation with individual data points. Horizontal bars represent the result of a non-
635 parametric Kruskal-Wallis test *** $p < 0.001$, ** $p < 0.01$



636

637

638

639

640 **Supporting information**

641

642 **Table S1 Symptomatic and asymptomatic samples collected and assayed by RT-QPCR**
643 **during year 2 and year 3 follow-up period**

| Sample Type | Total Diarrhea Recorded | Samples Collected | Samples not Collected | RT_QPCR Assay | Sample not Assayed |
|----------------------|--------------------------------|--------------------------|------------------------------|----------------------|---------------------------|
| Year 2 | | | | | |
| Symptomatic | 3763 | 3148 (83.66%) | 615 | 3132 | 16 (0.5%) |
| Sub-clinical* | NA | 15312 (97.58%) | 318 | 14638 | 674 (4.4%) |
| Year3 | | | | | |
| Symptomatic | 3578 | 3148 (83.96%) | 574 | 2978 | 26 (0.9%) |
| Sub-clinical* | NA | 14473 (97.94%) | 305 | 13806 | 667(4.6%) |

644

645

***Monthly Stool Samples**

646
647
648
649
650


Table S2. Regression Analysis using selected predictors to test the association of all cause diarrhea and HAZ at year 3

| Parameter | Effect (95% Confidence Interval) | P Value |
|---------------------------------|---|----------------|
| All cause diarrhea [#] | -0.008 (-0.023, 0.008) | 0.3357 |
| Child LAZ at Birth | 0.245 (0.151, 0.339) | <0.0001 |
| Maternal Weight | 0.017 (0.007, 0.027) | 0.001 |
| Maternal Height | 0.037 (0.019, 0.056) | 0.0001 |
| Maternal Education | 0.233 (0.020, 0.446) | 0.0323 |
| Household income | 0.001 (0.000, 0.002) | 0.079 |
| Treated water | 0.205 (-0.003, 0.413) | 0.0537 |

651 # diarrheal episodes (all-cause) were not significantly associated with HAZ at year 3
652
653


654 Table S1: **Symptomatic and asymptomatic samples collected during year 3**
655 Table S2: **Multivariable analysis of total all-cause diarrhea and HAZ at year 3**
656 Fig S1: **Flow chart of stool processing and molecular testing**
657 Fig S2: **Flow chart of stool TNA extraction procedure using QIAamp Fast DNA Stool Mini**
658 **Kit from fresh or frozen stool samples.**
659 Fig S3: **Flow chart of Multiplex qPCR of *Cryptosporidium*, *Giardia*, *Entamoeba histolytica***
660 **by targeting the 18S gene**
661 Fig S4 **Parasite burden in diarrheal and sub-clinical infections**
662 Fig S5 **Distribution of repeated *Cryptosporidium* infections**
663 Fig S6 **Recurrent cryptosporidiosis results in greater growth faltering**
664 Fig S7: **Comparison of cryptosporidiosis associated growth-faltering in diarrheal and**
665 **sub-clinical infections**
666 Fig S8 **Cryptosporidiosis was associated with chronic but not acute malnutrition at year**
667 **3**
668 Fig S9 **Low anti-Cryptosporidium IgA levels after an infection were associated with a**
669 **subsequent increase in cryptosporidiosis-associated growth-faltering**
670

671 **Fig S1: Flow chart of stool processing and molecular testing**




672
673

674 Fig S2: Flow chart of stool TNA Extraction procedure using QIAamp Fast DNA Stool Mini
675 Kit from fresh or frozen stool samples.



676


677 Fig S3: Flow chart of Multiplex qPCR of *Cryptosporidium*, *Giardia*, *Entamoeba histolytica*
678 by targeting the 18S gene
679




680
681

682 **Fig S4. Parasite burden in diarrheal and sub-clinical infections**

683 Relationship between Parasite Burden and the number of recurrent *Cryptosporidium* infections.
684 Each symbol represents the first detectable sample of an individual infection. Y-axis,
685 quantitative cycle of the diagnostic pan-Cryptosporidium PCR assay (Cq). X-axis, the total
686 number of *Cryptosporidium* infections. The infection was designated as either diarrheal (red) or
687 sub-clinical (green) based on the current infection phenotype. The data from diarrheal cases
688 was offset to improve data visualization. To account for within-child correlations among
689 repeated *Cryptosporidium* infections, the generalized estimating equation (GEE) method for
690 repeated measurements were used with exchangeable correlation structure. As the intercept of
691 the diarrheal and sub-clinical models was not statistically different the common intercept (27.02 ± 0.45)
692 was used. The slope of the data derived from the sub-clinical (1.9 ± 0.2) and diarrheal
693 (1.49 ± 0.31) exchangeable models were not significantly different from each other ($p=0.071$)
694 although both were statistically different from zero ($p<0.0001$).



695
696
697
698




699
700
701
702
703
704
705
706
707
708
709
710
711
712

Fig S5. Distribution of repeated *Cryptosporidium* infections

X axis child age in months; left y-axis child HAZ scores; right y-axis frequency of *Cryptosporidium* (diarrheal and sub-clinical) infections (shown as the number that occurred per the age of the child in months). All graphs include as a reference the HAZ score of children where no *Cryptosporidium* infections were detected (green circle and line). *Cryptosporidium* infections: Light blue triangle dotted blue connection line: infection one; purple circle and dotted line: infection two; light red square and dotted line: infection three; black triangle and dotted line: infection four A) blue symbol and solid line HAZ score of children who had one *Cryptosporidium* infections by 3 years of age B) purple square and solid line HAZ score of children who had two *Cryptosporidium* infections by three years of age C) red square and solid line HAZ score of children who had three *Cryptosporidium* infections by three years of age D) black square and solid line HAZ score of children who had four *Cryptosporidium* infections by three years of age


713
714
715



716

717 **Fig S6. Recurrent cryptosporidiosis results in greater growth faltering** Each symbol
718 represents a single child. Box plot comparing the height for age z score at 3 years (HAZ) (Y-
719 axis) mean and standard deviation shown Children are considered to be at Risk for malnutrition
720 is they have a HAZ score <-1 and malnourished at HAZ<-2: orange box: 3-year HAZ score -1 to
721 -2; red box 3-year HAZ score < -2. X-axis Number of Cryptosporidium infections. Bar indicates
722 the result of a non-parametric Kruskal-Wallis test for multiple comparisons * indicates $p < 0.05$ **
723 indicates $p < 0.01$
724


725



726

727 Fig S7: Comparison of cryptosporidiosis associated growth-faltering in diarrheal and
728 sub-clinical infections

729 Graphs show results from a simple linear regression with each symbol representing a single child.
730 Black symbols represent children who were never infected or had sub-clinical infections. The
731 blue symbols indicate children who have had one or more than one episodes of diarrhea-
732 associated cryptosporidiosis. Height for age (HAZ) z score at 3 years is shown on the Y-axis. The
733 slope of the diarrheal-associated and sub-clinical groups are identical. Pooled Slope: -0.1545.
734 Children are considered to be at Risk for malnutrition if they have a HAZ score <-1 and
735 malnourished at HAZ -2: orange box: 3-year HAZ score -1 to -2 ; red box: 3-year HAZ score < -
736 2. X-axis indicates number of *Cryptosporidium* infections
737




738
739
740
741
742
743
744
745
746
747
748
749
750

Fig S8. **Cryptosporidiosis was associated with chronic but not acute malnutrition at year 3.**


Graphs show results from a simple linear regression with each symbol representing a single child X-axis indicates number of *Cryptosporidium* infections A) Y-axis MUACZ circumference of the mid-upper arm (muscle wasting) B) Y-axis WAZ score (low weight for age) a measure of acute and chronic malnutrition C) Y-axis BAZ (body mass index for age) D) Y-axis WHZ score (low weight for height: wasting) a measure of acute malnutrition

751 Fig S9. **Low anti-Cryptosporidium IgA levels after an infection were associated with a**
752 **subsequent increase in cryptosporidiosis-associated growth-faltering**
753 Bar graphs (indicating data mean \pm standard deviation) with individual data points. Each symbol
754 on the box plot represents a child. On the X-axis values are shown for children in Groups 1 and
755 2 in both year one and year 3. Groups on the X-axis refers to the values obtained the end of the
756 first and third years of life. Y-axis represents the growth faltering (HAZ). Horizontal bars
757 represent the result of a non-parametric Kruskal-Wallis test *** indicates $p < 0.001$ ** indicates
758 $p < 0.01$ * $p < 0.05$
759

760 A) Group 1 children had higher than average levels of fecal anti-IgA Cp23. Group2a children
761 were negative by diagnostic surveillance by qPCR and anti-Cp23 antibodies at year one
762 Group2b were positive by qPCR but had nevertheless low levels of anti-Cp23 antibodies.



763 B) Group 1 children had higher than average levels of fecal anti-IgA Cp17. Group2a children
764 were negative by diagnostic surveillance by qPCR and anti-Cp17 antibodies at year one
765 Group2b were positive by qPCR but had nevertheless low levels of anti-Cp17 antibodies.
766
767



768